Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach

Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach

The treatment of acute myeloid leukemia (AML) in Jehovah’s Witness (JW) patients poses unique challenges due to their refusal of blood transfusions. This case series reports the outcomes of four older JW patients with AML treated with azacitidine (Aza) and venetoclax (Ven), including two with hyperl...

Full description

Saved in:
Bibliographic Details
Main Authors: Aditi Sharma, Danielle Blake, Jay Yang
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Hemato
Subjects:
AML
acute myeloid leukemia
Jehovah’s Witness
venetoclax
hypomethylating agent
azacitidine
Online Access:https://www.mdpi.com/2673-6357/6/2/16
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items